* The labeling of omalizumab (Xolair), a drug used to treat allergic asthma, now carries a warning that its use may slightly increase the risk of cardiovascular complications. The drug may also pose an increased risk of inducing cancer.
Un proyecto de la Biblioteca de la Universidad Complutense de Madrid